Historical DNA Links Colonial Graves to 1.3 Million Living Relatives and May Have Identified the Colony’s Second Governor

discovermagazine - Learn how researchers used DNA and 23andMe to connect 17th-century Maryland colonists to more than 1.3 million living people and potentially identify the colony’s second governor.

AI Summary: Ancient DNA from a colonial‑era burial site has been analyzed and linked to living descendants, potentially identifying one of the colony’s leaders. Among the finds is an 8‑year‑old African American boy buried with white colonists; researchers report his presence but cannot yet determine whether he was enslaved, prompting fresh questions about social status and burial practices.

Depressed mice successfully treated with smart contact lenses that zap their brains: New study

medicalxpress - Scientists in South Korea have developed experimental contact lenses designed to send electrical signals through the retina and into brain regions linked to mood. In mice, the technology appeared to improve depression-like behavior.

AI Summary: Preclinical studies report smart contact lenses that deliver tiny electrical signals can reduce depressive-like behaviors in mice, matching effects seen with standard antidepressants. Researchers caution the work is early — promising biologically, but still a long way from fashionable therapeutic eyewear for humans — and will require safety, dosing and translational studies before any clinic-ready hype.

Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer

oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]

AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.

Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds

medicalxpress - The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published in the New England Journal of …

AI Summary: A randomized trial shows the oral antiviral ensitrelvir, used as post‑exposure prophylaxis, reduced the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The finding suggests a practical option for preventing spread after close exposure, offering public‑health teams a less dramatic but highly useful tool than lockdowns.

BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

Ayisha Sharma / endpoints - BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in a rare but aggressive form of blood cancer, where AbbVie and Genentech’s Venclexta is used off-label. The FDA greenlit ...

AI Summary: BeOne Medicines secured FDA approval for a next-generation BCL2 inhibitor, positioning the drug as a direct challenge to AbbVie/Roche’s Venclexta franchise. The move reshuffles competitive dynamics in hematology, potentially offering clinicians an alternative and setting the stage for market share battles and payer negotiations. Expect aggressive positioning and head-to-head data requests.

Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial

Cyril Erameh / nature - Nature Medicine, Published online: 15 May 2026; doi:10.1038/s41591-026-04402-wAn open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was s…

AI Summary: An open-label, randomized Phase 2 trial of favipiravir for Lassa fever reported encouraging results, suggesting antiviral benefit where few options exist. The study offers early clinical proof-of-concept, especially important for endemic West African settings, and calls for larger trials to confirm efficacy, optimize dosing, and assess deployment logistics.